Market News AIOpen the app

Kairos Pharma had no sales last quarter and lost $2.0 million, which could worry investors.

ResultsRead the original at moomoo.com
Bad for KAPA

Kairos Pharma reported no revenue, and its operating loss and loss per share both grew from a year earlier. Revenue staying at zero does not counter the worsening losses.

KAPA · Kairos Pharma, Ltd.

AI read · Bad for KAPA

The AI's read

With no sales coming in, Kairos had no revenue to cover its costs. Its operating loss grew, and the loss per share also grew from a year earlier. Together, those figures point to worsening business results.

Get alerts for KAPA

Follow Kairos Pharma, Ltd. (KAPA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KAPA
Free on the App Store and Google Play, or on the web.